1Mon·
3
1 Comment

profile image
Poor analyst commentary.....NEW YORK (dpa-AFX Analyser) - US bank JPMorgan has left its rating for Carl Zeiss Meditec at "Underweight" with a price target of 56 euros ahead of the fourth quarter figures. For the 2023/24 financial year, reaching the lower end of the company's target range is more likely, as the medical technology market remains sluggish, analyst Anchal Verma wrote in a study published on Tuesday. The focus is likely to be on 2024/25 anyway, for which he has reduced his earnings forecast (adjusted EBIT) by around 5 percent. The consensus estimate is still too optimistic./edh/bek
•
3
•
Join the conversation